Research Analysts Set Expectations for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at William Blair issued their FY2024 EPS estimates for shares of CRISPR Therapeutics in a research report issued on Monday, December 9th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($4.66) per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.97) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.38) EPS and FY2025 earnings at ($3.31) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the firm posted ($1.41) earnings per share.

CRSP has been the subject of several other research reports. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Wednesday. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $77.93.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $47.78 on Wednesday. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -16.88 and a beta of 1.62. CRISPR Therapeutics has a 1 year low of $43.42 and a 1 year high of $91.10. The business’s 50 day simple moving average is $48.82 and its 200-day simple moving average is $51.33.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 in the last three months. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its stake in shares of CRISPR Therapeutics by 12.7% during the third quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock valued at $339,000 after purchasing an additional 800 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics during the 3rd quarter valued at $40,000. Sanctuary Advisors LLC boosted its position in CRISPR Therapeutics by 17.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock valued at $398,000 after acquiring an additional 1,258 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in shares of CRISPR Therapeutics by 11.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock valued at $139,000 after acquiring an additional 300 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after acquiring an additional 35,196 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.